Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vivos Therapeutics, Inc. on November 19, 2025. The filing serves to announce the Company's financial results for the third quarter ended September 30, 2025. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Littleton, Colorado.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report references a press release (Exhibit 99.1) containing the detailed financial results, but the text of the press release is not included in the provided source content.
Material Changes
No material changes versus the prior comparable period are described in the provided text. The filing solely indicates the issuance of a press release regarding Q3 2025 results.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. It explicitly states that the information in this report (including the referenced press release) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 19, 2025) for specific Q3 2025 revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm if the Company has provided updated full-year 2025 guidance in the referenced exhibit.